← Research
Feb 2000 Randomized Controlled Trial
Antidepressant Effects of Ketamine in Depressed Patients
Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH — Yale University School of Medicine
Published in Biological Psychiatry
Ketamine Depression
The first placebo-controlled, double-blind trial of an NMDA receptor antagonist for depression. 7 patients received a single IV dose of ketamine (0.5mg/kg) or saline in a crossover design; Hamilton Depression scores dropped 14 points on ketamine vs. 0 on placebo within three days — the foundational result behind every ketamine-for-depression program that followed, including Spravato.
Read the Full Paper at Biological Psychiatry